Envista Holdings Corporation
NVST Healthcare Medical Instruments & Supplies
Envista Holdings Corporation’s revenue for fiscal 2025 (year ended December 2025) was $2.7 billion, up 8.32% from fiscal 2024.
- Revenue
- +3.22%
- EPS
- +1,855.6%
- Free cash flow
- −6.48%
- Total debt
- −1.13%
Quarter to September 2026, against a year earlier
Follow NVST
Alert me
Envista Holdings Corporation (NVST) EV/EBITDA
As of 5 November 2026, Envista Holdings Corporation (NVST) trades at a EV/EBITDA of 10.3×. Over the past ten years it has ranged from 0.0× (June 2025) to 46.3× (December 2020); the current reading is higher than 20% of that period. That is below the Medical Instruments & Supplies industry median of 14.9× and above the Healthcare sector median of 8.4×.
EV/EBITDA, daily
Embed this chart
Annual newest first
| Period | EV/EBITDA | Change |
|---|---|---|
| FY2025 | 10.8× | — |
| FY2024 | 0.0× | — |
| FY2023 | 23.1× | 78.04% |
| FY2022 | 13.0× | (16.68%) |
| FY2021 | 15.6× | (45.46%) |
| FY2020 | 28.6× | 124.11% |
| FY2019 | 12.8× | — |
| FY2018 | 0.0× | — |
| FY2017 | 0.0× | — |
| FY2016 | 0.0× | — |
Quarterly newest first
| Period | EV/EBITDA | Change |
|---|---|---|
| Sep 2026 | 9.7× | (11.35%) |
| Jun 2026 | 10.9× | (6.33%) |
| Mar 2026 | 11.7× | 8.35% |
| Dec 2025 | 10.8× | (3.22%) |
| 28 more quarters | Free account |
Against its own ten years
EV/EBITDA against peers
| Company | EV/EBITDA |
|---|---|
| PLSE Pulse Biosciences, Inc compare | n/m |
| MMED MiniMed Group, Inc. compare | n/m |
| NVST Envista Holdings Corporation | 10.3× |
| STVN Stevanato Group S.p.A. compare | 11.3× |
| MMSI Merit Medical Systems, Inc. compare | 15.5× |
| ICUI ICU Medical, Inc. compare | 16.0× |
| TFX Teleflex Incorporated compare | 35.7× |
| WRBY Warby Parker Inc. compare | 50.2× |
| ATRC AtriCure, Inc. compare | 83.7× |
| Medical Instruments & Supplies industry median | 14.9× |
| Healthcare sector median | 8.4× |
| Market median | 10.9× |
What EV/EBITDA is
Enterprise Value over EBITDA tells an investor how the market values a whole company, with debt added and cash taken off, against its operating earnings.
((Stock Price × Shares (Basic, Weighted) (latest quarter)) + (Long Term Debt (Total) (latest quarter) + Current Part of Debt (latest quarter)) − Cash & Short Term Investments (latest quarter)) ÷ EBITDA (TTM)
More on NVST
- Revenue
- Net income
- EPS (diluted)
- EBITDA
- Free cash flow
- Operating cash flow
- Gross margin
- Operating margin
- Net margin
- Free cash flow margin
- P/E ratio
- P/S ratio
- P/B ratio
- Price to free cash flow
- EV/Sales
- EV/FCF
- Return on equity
- Return on assets
- Return on invested capital
- Debt to equity
- Current ratio
- Total debt
- Shares outstanding
- Book value per share
- Revenue growth
- Piotroski F-score
- Altman Z-score
- Beneish M-score
- The full statement